Chronic myelogenous leukemia (CML) is a clonal hematopoietic disorder caused by the
reciprocal translocation between chromosome 9 and 22. As a result of this translocation, a …

Although imatinib has become the current standard treatment for chronic myeloid leukemia
(CML), there is limited information regarding its efficacy and safety among Japanese …

Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …

Aim: Sixty nine patients who were diagnosed with CML and were treated with first-
generation TKI (in the form of imatinib mesylate) as initial treatment between 2006 and 2018 …

Chronic myelogenous leukemia (CML) is a clonal proliferative disease originating from a
pluripotential stem cell in which a 9: 22 translocation, Philadelphia (Ph) chromosome, results …

Imatinib therapy for chronic myeloid leukemia: where do we go now? - Abstract - Europe PMC
Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers Help …

BACKGROUND There is paucity of data from developing countries on the efficacy and safety
of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study …

A prospective multicenter Phase II study was performed to examine the efficacy and safety of
imatinib therapy in newly diagnosed Japanese patients with chronic‐phase CML. Patients …

Purpose Imatinib is remarkably effective in treating newly diagnosed patients with chronic
myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come …

The International Randomized Study of Interferon and STI571 (IRIS) study prospectively
compared imatinib with interferon-alpha/low-dose cytarabine (IFN/LDAC) in 1,106 newly …